CIRM votes to shift stem cell grants toward clinical development side

The California Institute for Regenerative Medicine (CIRM) is shifting away somewhat from the kinds of stem cell grants it has previously funded. In late May, the board voted without objections on a new strategic plan designed to reduce or end spending on basic research, facilities and training, and focus more of the money on clinical development, Nature reports. The change is a big departure from the previous 5 years, where almost 50% of the $1.3 billion the agency awarded over that period focused more on helping programs ramp up with new research facilities and training, according to the piece. Story

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.